Cell specific-targeted therapy (CSTT) offers an attractive method for targeting the cell types most affected by stroke while avoiding off-target effects. While significant progress has been made within intravenous and endovascular therapy aimed at revascularization after stroke, these treatments do not address infarct evolution and secondary cell damage and brain injury after stroke 1, 2, 3. Ischemic stroke is a leading cause of death worldwide, causing significant morbidity and mortality.
0 kommentar(er)
